var data={"title":"Irinotecan (conventional): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Irinotecan (conventional): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6402?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=irinotecan-conventional-drug-information\" class=\"drug drug_general\">see &quot;Irinotecan (conventional): Drug information&quot;</a> and <a href=\"topic.htm?path=irinotecan-conventional-patient-drug-information\" class=\"drug drug_patient\">see &quot;Irinotecan (conventional): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708954\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Diarrhea:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Early and late forms of diarrhea can occur. Early diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine. Late diarrhea can be life-threatening and should be treated promptly with loperamide. Monitor patients with diarrhea and give fluid and electrolytes as needed. Institute antibiotic therapy if patients develop ileus, fever, or severe neutropenia. Interrupt irinotecan and reduce subsequent doses if severe diarrhea occurs.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Severe myelosuppression may occur.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184455\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Camptosar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184456\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Camptosar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048038\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Camptothecin</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Topoisomerase I Inhibitor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048030\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=irinotecan-conventional-drug-information\" class=\"drug drug_general\">see &quot;Irinotecan (conventional): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> A reduction in the starting dose by at least one dose level should be considered for prior pelvic/abdominal radiotherapy, performance status of &ge;2, or known homozygosity for UGT1A1*28 allele. Consider prophylaxis with oral third generation cephalosporins (McGregor 2012; McNall-Knapp 2010), and/or atropine IV or SubQ for treatment in patients with cholinergic symptoms (eg, increased salivation, diaphoresis, abdominal cramping) or diarrhea. Details concerning dosage in combination regimens should also be consulted. Irinotecan (conventional) and irinotecan (liposomal) are <b>NOT</b> interchangeable. Dosing differs between formulations; verify intended product and dose prior to preparation and administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neuroblastoma, refractory or palliative:</b> Limited data available<b>: </b>Children &ge;2 years and Adolescents: IV: 50 mg/m<sup>2</sup> over 1 hour once daily on days 1 to 5 (5 doses), in combination with temozolomide; repeat cycle every 21 days (Kushner 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Solid tumor or CNS tumor; refractory or relapsed (low-dose, protracted schedule):</b> Limited data available: Children &ge;2 years and Adolescents: IV: 15 mg/m<sup>2</sup> over 1 hour once daily on days 1 to 5 (5 doses) and days 8 to 12 (5 doses) of a 28-day treatment cycle; in the trial, a maximum dose of 30 mg/dose was reported; may repeat cycle if tolerated in combination with temozolomide and vincristine (McNall-Knapp 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Solid tumor or CNS tumor; refractory or relapsed:</b> Limited data available: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Daily regimen:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Children &ge;2 years and Adolescents: 50 mg/m<sup>2</sup> over 1 hour once daily on days 1 to 5 (5 doses) as a single agent; repeat cycle every 21 days (Kushner 2005); some protocols include combination with temozolomide (Morganstern 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: Children and Adolescents: 90 mg/m<sup>2 </sup>once daily on days 1 to 5 (5 doses) repeat every 3 weeks; in combination with vincristine and temozolomide (Wagner 2010a)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weekly regimen (Bomgaars 2006):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Heavily pretreated patients (eg, &ge;2 prior chemotherapy regimens): IV: 125 mg/m<sup>2</sup>/dose once weekly for 4 weeks over 90 minutes, repeat cycle every 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Less-heavily pretreated patients (&le;2 prior chemotherapy regimens): IV: 160 mg/m<sup>2</sup>/dose once weekly for 4 weeks over 90 minutes, repeat cycle every 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rhabdomyosarcoma, refractory or metastatic:</b> Limited data available: Children and Adolescents: IV: 50 mg/m<sup>2</sup> once daily for 5 days (maximum dose: 100 mg/dose) on protocol specific weeks (Mascarenhas 2010; Weigel 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Colorectal cancer, metastatic (single-agent therapy):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weekly regimen: 125 mg/m<sup>2</sup> over 90 minutes on days 1, 8, 15, and 22 of a 6-week treatment cycle (may adjust upward to 150 mg/m<sup>2</sup> if tolerated)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adjusted dose level -1: 100 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adjusted dose level -2: 75 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Further adjust to 50 mg/m<sup>2</sup> (in decrements of 25 to 50 mg/m<sup>2</sup>) if needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Once-every-3-week regimen: 350 mg/m<sup>2</sup> over 90 minutes, once every 3 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adjusted dose level -1: 300 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adjusted dose level -2: 250 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Further adjust to 200 mg/m<sup>2</sup> (in decrements of 25 to 50 mg/m<sup>2</sup>) if needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Colorectal cancer, metastatic (in combination with fluorouracil and leucovorin):</b> IV: Six-week (42-day) cycle:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Regimen 1: 125 mg/m<sup>2</sup> over 90 minutes on days 1, 8, 15, and 22; to be given in combination with bolus leucovorin and fluorouracil (leucovorin administered immediately following irinotecan; fluorouracil immediately following leucovorin)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adjusted dose level -1: 100 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adjusted dose level -2: 75 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Further adjust if needed in decrements of ~20%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Regimen 2: 180 mg/m<sup>2</sup> over 90 minutes on days 1, 15, and 29; to be given in combination with infusional leucovorin and bolus/infusion fluorouracil (leucovorin administered immediately following irinotecan; fluorouracil immediately following leucovorin)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adjusted dose level -1: 150 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adjusted dose level -2: 120 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Further adjust if needed in decrements of ~20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal impairment: There are no dosage adjustments provided in manufacturer&rsquo;s labeling (has not been studied); use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis: Use in patients with dialysis is not recommended by the manufacturer; however, literature suggests reducing weekly dose from 125 mg/m<sup>2</sup> to 50 mg/m<sup>2</sup> and administering after hemodialysis or on nondialysis days (Janus 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer&rsquo;s labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Liver metastases with normal hepatic function: No adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bilirubin &gt;ULN to &le;2 mg/dL: Consider reducing initial dose by one dose level.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bilirubin &gt;2 mg/dL: Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: The following adjustments have also been recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bilirubin 1.5 to 3 mg/dL: Administer 75% of dose (Floyd 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bilirubin 1.51 to 3 times ULN: Reduce dose from 350 mg/m<sup>2</sup> every 3 weeks to 200 mg/m<sup>2</sup> every 3 weeks (Raymond 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available. See tables for adult dosage recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">It is recommended that new courses begin only after the granulocyte count recovers to &ge;1,500/mm<sup>3</sup>, the platelet counts recover to &ge;100,000/mm<sup>3</sup>, and treatment-related diarrhea has fully resolved. Depending on the patient's ability to tolerate therapy, adult doses should be adjusted in increments of 25 to 50 mg/m<sup>2</sup>. Treatment should be delayed 1 to 2 weeks to allow for recovery from treatment-related toxicities. If the patient has not recovered after a 2-week delay, consider discontinuing irinotecan. See tables for adult dosage recommendations.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Colorectal Cancer: Single-Agent Schedule: Recommended <span style=\"text-decoration: underline\">Adult</span> Dosage Modifications<sup>A</sup></caption>\n      <col></col>\n      <col></col>\n      <col></col>\n      <col></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Toxicity NCI Grade<sup>B </sup> (Value)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">During a Cycle of Therapy</p></th>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">At Start of Subsequent Cycles of Therapy (After Adequate Recovery), Compared to Starting Dose in Previous Cycle<sup>A</sup></p></th></tr>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Weekly</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Weekly</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Once Every 3 Weeks</p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"4\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>A</sup>All dose modifications should be based on the worst preceding toxicity.</p></td></tr>\n        <tr>\n          <td colspan=\"4\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>B</sup>National Cancer Institute Common Toxicity Criteria (version 1.0).</p></td></tr>\n        <tr>\n          <td colspan=\"4\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>C</sup>Excludes alopecia, anorexia, asthenia.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">No toxicity</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Maintain dose level</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&uarr; 25 mg/m<sup>2</sup> up to a maximum dose of 150 mg/m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Maintain dose level</p></td></tr>\n        <tr>\n          <td colspan=\"4\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <b>Neutropenia</b></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 (1,500 to 1,999/mm<sup>3</sup>)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Maintain dose level</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Maintain dose level</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Maintain dose level</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 (1,000 to 1,499/mm<sup>3</sup>)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&darr; 25 mg/m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Maintain dose level</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Maintain dose level</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 (500 to 999/mm<sup>3</sup>)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Omit dose until resolved to &le; grade 2, then &darr; 25 mg/m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&darr; 25 mg/m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&darr; 50 mg/m<sup>2</sup></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4 (&lt;500/mm<sup>3</sup>)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Omit dose until resolved to &le; grade 2, then &darr; 50 mg/m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&darr; 50 mg/m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&darr; 50 mg/m<sup>2</sup></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Neutropenic Fever</b> (grade 4 neutropenia and &ge; grade 2 fever)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Omit dose until resolved, then &darr; 50 mg/m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&darr; 50 mg/m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&darr; 50 mg/m<sup>2</sup></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Other Hematologic Toxicities</b></p></td>\n          <td colspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">Dose modifications for leukopenia, thrombocytopenia, and anemia during a course of therapy and at the start of subsequent courses of therapy are also based on NCI toxicity criteria and are the same as recommended for neutropenia above.</p></td></tr>\n        <tr>\n          <td colspan=\"4\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <b>Diarrhea</b></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 (2-3 stools/day &gt;pretreatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Maintain dose level</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Maintain dose level</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Maintain dose level</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 (4-6 stools/day &gt;pretreatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&darr; 25 mg/m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Maintain dose level</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Maintain dose level</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 (7-9 stools/day &gt; pretreatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Omit dose until resolved to &le; grade 2, then &darr; 25 mg/m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&darr; 25 mg/m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&darr; 50 mg/m<sup>2</sup></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4 (&ge;10 stools/day &gt; pretreatment)</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Omit dose until resolved to &le; grade 2, then &darr; 50 mg/m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&darr; 50 mg/m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&darr; 50 mg/m<sup>2</sup></p></td></tr>\n        <tr>\n          <td colspan=\"4\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <b>Other Nonhematologic Toxicities<sup>C </sup></b></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Grade 1</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Maintain dose level</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Maintain dose level</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Maintain dose level</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Grade 2</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&darr; 25 mg/m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&darr; 25 mg/m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&darr; 50 mg/m<sup>2</sup></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Grade 3</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Omit dose until resolved to &le; grade 2, then &darr; 25 mg/m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&darr; 25 mg/m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&darr; 50 mg/m<sup>2</sup></p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Grade 4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Omit dose until resolved to &le; grade 2, then &darr; 50 mg/m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&darr; 50 mg/m<sup>2</sup></p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&darr; 50 mg/m<sup>2</sup></p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184432\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Camptosar: 40 mg/2 mL (2 mL); 100 mg/5 mL (5 mL); 300 mg/15 mL (15 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 40 mg/2 mL (2 mL); 100 mg/5 mL (5 mL); 500 mg/25 mL (25 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 40 mg/2 mL (2 mL); 100 mg/5 mL (5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184417\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048042\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Irinotecan is associated with a moderate emetic potential (Basch 2011; Dupuis 2011; Roila 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Parenteral: IV infusion: Infuse usually over 90 minutes; some pediatric protocols infuse the dose over 1 hour (Kushner 2005; McNall-Knapp 2010); consult specific protocol. Higher incidence of cholinergic symptoms (increased salivation, rhinitis, miosis, diaphoresis, abdominal cramping) have been reported with more rapid infusion rates; consider prophylaxis with oral cephalosporin antibiotics or rescue atropine for acute-onset diarrhea.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132622\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184448\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Store intact vials at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light; retain vials in original carton until use. Solutions diluted in NS may precipitate if refrigerated. Solutions diluted in D5W are stable for 24 hours at room temperature or 48 hours under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F), although the manufacturer recommends use within 24 hours if refrigerated, or within 4 to 12 hours (manufacturer dependent; refer to specific prescribing information) at room temperature (including infusion time) only if prepared under strict aseptic conditions (eg, laminar flow hood). Do not freeze.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extemporaneously prepared oral solutions (pediatric): Undiluted commercially available injectable solution prepared in oral syringes is stable for 21 days under refrigeration (Wagner 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048041\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of metastatic carcinoma of the colon or rectum (FDA approved in adults); has also been used in the treatment of refractory solid tumor, neuroblastoma, or CNS  tumor and refractory or metastatic rhabdomyosarcoma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3401643\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Conventional formulation (Camptosar) may be confused with the liposomal formulation (Onivyde)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Irinotecan (conventional) may be confused with irinotecan (liposomal), topotecan</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Irinotecan (conventional) and irinotecan (liposomal) are <b>NOT</b> interchangeable. Dosing differs between formulations; verify intended product and dose prior to preparation and administration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184499\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">In limited pediatric experience, dehydration (often associated with severe hypokalemia and hyponatremia) was among the most significant grade 3/4 adverse events.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Edema, hypotension, thromboembolism, vasodilatation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, cholinergic syndrome (includes diaphoresis, flushing, increased peristalsis, lacrimation, miosis, rhinitis, sialorrhea), confusion, dizziness, drowsiness, headache, insomnia, pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, diaphoresis, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Dehydration, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, abdominal distention, abdominal pain, anorexia, constipation, diarrhea, dyspepsia, flatulence, mucositis, nausea, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, febrile neutropenia, hemorrhage, leukopenia, neutropenia, neutropenic infection, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Ascites, increased serum alkaline phosphatase, increased serum AST, increased serum bilirubin, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Back pain, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, dyspnea, rhinitis, pneumonia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute renal failure, anaphylactoid reaction, anaphylaxis, angina pectoris, arterial thrombosis, bradycardia, cardiac arrhythmia, cerebral infarction, cerebrovascular accident, circulatory shock, colitis, embolism, gastrointestinal hemorrhage, gastrointestinal obstruction, hepatomegaly, hyperglycemia, hypersensitivity reaction, hyponatremia, immune thrombocytopenia, increased amylase, increased serum ALT, increased serum lipase, interstitial pulmonary disease, intestinal obstruction, intestinal perforation, ischemic colitis, ischemic heart disease, lymphocytopenia, megacolon, myocardial infarction, pancreatitis, paresthesia, peripheral vascular disease, pulmonary embolism; pulmonary toxicity (includes dyspnea, fever, reticulonodular infiltrates on chest x-ray), renal insufficiency, thrombophlebitis, thrombosis, typhlitis (including neutropenic typhlitis), ulcerative colitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184438\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Known hypersensitivity to irinotecan or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Coadministraton with azole antifungals (ketoconazole, fluconazole, itraconazole); patients with hereditary fructose intolerance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184421\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: May cause severe myelosuppression.</b> Deaths due to sepsis following severe neutropenia have been reported. Complications due to neutropenia should be promptly managed with antibiotics. Therapy should be temporarily withheld if neutropenic fever occurs or if the absolute neutrophil count is &lt;1,000/mm<sup>3</sup>; reduce the dose upon recovery to an absolute neutrophil count &ge;1,000/mm<sup>3</sup>. Patients who have previously received pelvic/abdominal radiation therapy have an increased risk of severe bone marrow suppression; the incidence of grade 3 or 4 neutropenia was higher in patients receiving weekly irinotecan who have previously received pelvic/abdominal radiation therapy. Concurrent radiation therapy is not recommended with irinotecan (based on limited data).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diarrhea:<b> [US Boxed Warning]: Severe diarrhea may be dose-limiting and potentially fatal; early-onset and late-onset diarrhea may occur. Early diarrhea occurs during or within 24 hours of receiving irinotecan and is characterized by cholinergic symptoms; may be prevented or treated with atropine. Late diarrhea may be life-threatening and should be promptly treated with loperamide. Antibiotics may be necessary if patient develops ileus, fever, or severe neutropenia. Interrupt treatment and reduce subsequent doses for severe diarrhea.</b> Early diarrhea is generally transient and rarely severe; cholinergic symptoms may include increased salivation, rhinitis, miosis, diaphoresis, flushing, abdominal cramping, and lacrimation; bradycardia may also occur. Cholinergic symptoms may occur more frequently with higher irinotecan doses. Late diarrhea occurs more than 24 hours after treatment, which may lead to dehydration, electrolyte imbalance, or sepsis. Late diarrhea may be complicated by colitis, ulceration, bleeding, ileus, obstruction, or infection; cases of megacolon and intestinal perforation have been reported. The median time to onset for late diarrhea is 5 days with every 3 week irinotecan dosing and 11 days with weekly dosing. Advise patients to have loperamide readily available for the treatment of late diarrhea. Patients with diarrhea should be carefully monitored and treated promptly; may require fluid and electrolyte therapy. Bowel function should be returned to baseline for at least 24 hours prior to resumption of weekly irinotecan dosing. Avoid diuretics and laxatives in patients experiencing diarrhea.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Irinotecan is an irritant. Avoid extravasation; if extravasation occurs, the manufacturer recommends flushing the external site with sterile water and applying ice.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Irinotecan is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011; Hesketh 2017; Roila 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Severe hypersensitivity reactions (including anaphylaxis) have occurred. Monitor closely; discontinue therapy if hypersensitivity occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: Fatal cases of interstitial pulmonary disease (IPD)-like events have been reported with single-agent and combination therapy. Risk factors for pulmonary toxicity include preexisting lung disease, use of pulmonary toxic medications, radiation therapy, and colony-stimulating factors. Patients with risk factors should be monitored for respiratory symptoms before and during irinotecan treatment. Promptly evaluate progressive changes in baseline pulmonary symptoms or any new-onset pulmonary symptoms (eg, dyspnea, cough, fever). Discontinue all chemotherapy if IPD is diagnosed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: Renal impairment and acute renal failure have been reported, possibly due to dehydration secondary to diarrhea. Use with caution in patients with renal impairment; not recommended in patients on dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolism: Thromboembolic events have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bowel obstruction: Patients with bowel obstruction should not be treated with irinotecan until resolution of obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; exposure to the active metabolite (SN-38) is increased; toxicities may be increased. Patients with even modest elevations in total serum bilirubin levels (1 to 2 mg/dL) have a significantly greater likelihood of experiencing first-course grade 3 or 4 neutropenia than those with bilirubin levels that were &lt;1 mg/dL. Patients with abnormal glucuronidation of bilirubin, such as those with Gilbert syndrome, may also be at greater risk of myelosuppression when receiving therapy with irinotecan. Use caution when treating patients with known hepatic dysfunction or hyperbilirubinemia; dosage adjustments should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. CYP3A4 enzyme inducers may decrease exposure to irinotecan and SN-38 (active metabolite); enzyme inhibitors may increase exposure. For use in patients with CNS tumors (off-label use), selection of antiseizure medications that are not enzyme inducers is preferred.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Patients &gt;65 years of age are at greater risk for early and late diarrhea. A dose reduction is recommended for patients &ge;70 years of age receiving the every-3-week regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patients homozygous/heterozygous for the UGT1A1*28 allele: Patients homozygous for the UGT1A1*28 allele are at increased risk of neutropenia; consider reducing the initial dose by at least one dose level for both single-agent and combination regimens. Heterozygous carriers of the UGT1A1*28 allele may also be at increased neutropenic risk; however, most patients have tolerated normal starting doses. A test is available for clinical determination of UGT phenotype, although a dose reduction is already recommended in patients who have experienced toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pelvic/abdominal radiation recipients: Use with caution in patients who have previously received pelvic/abdominal radiation; may increase risk of severe myelosuppression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Performance status: Higher rates of hospitalization, neutropenic fever, thromboembolism, first-cycle discontinuation, and early mortality were observed in patients with a performance status of 2 than in patients with a performance status of 0 or 1.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conventional vs liposomal formulation dosing: Irinotecan (conventional) and irinotecan (liposomal) are <b>NOT</b> interchangeable. Dosing differs between formulations; verify intended product and dose prior to preparation and administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sorbitol: Product contains sorbitol; do not use in patients with hereditary fructose intolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Except as part of a clinical trial, use in combination with the fluorouracil and leucovorin administered for 4 or 5 consecutive days every 4 weeks (&ldquo;Mayo Clinic&rdquo; regimen) is not recommended due to increased toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26023250\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In pediatric patients, provide antibiotic support if patient develops persistent diarrhea (grade 3 or 4), ileus, fever, sepsis, or severe neutropenia; cefixime (8 mg/kg/day, maximum dose: 400 mg) has been used in children as prophylaxis for diarrhea beginning 5 days prior to irinotecan therapy and continued throughout course (Wagner 2008); cefpodoxime (10 mg/kg/day divided twice daily, maximum dose: 200 mg) has also been used (McNall-Knapp 2010; Wagner 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184487\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of BCRP/ABCG2, CYP3A4 (major), OATP1B1/SLCO1B1, P-glycoprotein/ABCB1, UGT1A1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184426\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13238&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Irinotecan Products.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Irinotecan Products.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifapentine: May decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be reduced. Rifapentine may decrease the serum concentration of Irinotecan Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SORAfenib: May increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be increased. SORAfenib may increase the serum concentration of Irinotecan Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be reduced. St John's Wort may decrease the serum concentration of Irinotecan Products.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">UGT1A1 Inhibitors: May increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be increased. UGT1A1 Inhibitors may increase the serum concentration of Irinotecan Products.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184428\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184440\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Information related to the use of irinotecan (conventional) during pregnancy is limited (Cirillo 2012; Taylor 2009). May cause fetal harm if administered during pregnancy. Women of childbearing potential should avoid becoming pregnant while receiving treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048037\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs of diarrhea and dehydration, serum electrolytes, serum BUN and creatinine; infusion site for signs of inflammation; CBC with differential and platelet count, hemoglobin, liver function tests, and serum bilirubin</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A test is available for genotyping of UGT1A1; however, guidelines for use are not established and not recommended; in patients who have experienced toxicity, a dose reduction is recommended</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184420\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Irinotecan and its active metabolite (SN-38) bind reversibly to topoisomerase I-DNA complex preventing religation of the cleaved DNA strand. This results in the accumulation of cleavable complexes and double-strand DNA breaks. As mammalian cells cannot efficiently repair these breaks, cell death consistent with S-phase cell cycle specificity occurs, leading to termination of cellular replication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184437\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents: ~37 L/m<sup>2</sup> (range: 15.2 to 77 L/m<sup>2</sup>) (Ma 2000); distributes to pleural fluid, sweat, and saliva</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 33 to 150 L/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding, plasma: Predominantly albumin; Irinotecan: 30% to 68%, SN-38 (active metabolite): ~95%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Primarily hepatic to SN-38 (active metabolite) by carboxylesterase enzymes; may also undergo CYP3A4-mediated metabolism to inactive metabolites (one of which may be hydrolyzed to release SN-38). SN-38 undergoes conjugation by UDP-glucuronosyl transferase 1A1 (UGT1A1) to form a glucuronide metabolite. SN-38 is increased by UGT1A1*28 polymorphism (10% of North Americans are homozygous for UGT1A1*28 allele).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Median: 9%; increased in presence of gefitinib (median: 42%) (Furman 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents (Ma 2000): Irinotecan: 2.66 hours (range: 1.82 to 4.47 hours); SN-38 (active metabolite): 1.58 hours (range: 0.29 to 8.28 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Irinotecan: 6 to 12 hours; SN-38: ~10 to 20 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Irinotecan: Oral: Children and Adolescents: 3 hours (Wagner 2010a)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SN-38: Following 90-minute infusion: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine: Irinotecan (11% to 20%), metabolites (SN-38 &lt;1%, SN-38 glucuronide, 3%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323228\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Camptosar Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/2 mL (2 mL): $30.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (5 mL): $44.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/15 mL (15 mL): $134.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Irinotecan HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/2 mL (2 mL): $19.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (5 mL): $42.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/25 mL (25 mL): $174.02</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184441\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actatecan (ID);</li>\n      <li>Ai Li (CN);</li>\n      <li>Calmtop (KR);</li>\n      <li>Campto (AE, AT, BE, BF, BG, BH, BJ, CH, CI, CN, CY, CZ, DE, DK, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, HR, ID, IE, IL, IT, JO, JP, KE, KR, KW, LB, LR, LU, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, PH, PK, PL, PT, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, TH, TN, TR, TW, TZ, UG, VN, ZA, ZM, ZW);</li>\n      <li>Camptosar (AR, AU, BO, BR, CL, CO, CR, DO, GT, MX, NI, NZ, PA, PE, PR, QA, SV, UY, VE);</li>\n      <li>Camtecan (KR);</li>\n      <li>Efixano (PY);</li>\n      <li>Etoniri (MX);</li>\n      <li>Herocan (TW);</li>\n      <li>Imocam (VN);</li>\n      <li>Indotecan (KR);</li>\n      <li>Innocan (TW);</li>\n      <li>Irenax (TW);</li>\n      <li>Irican (PH);</li>\n      <li>Iricip (LK);</li>\n      <li>Irino (LK, TH);</li>\n      <li>Irinocyt (CO);</li>\n      <li>Irinogen (EC, PY);</li>\n      <li>Irinoll (TH);</li>\n      <li>Irinotel (ET, IN, JO, LK, TH, TW, ZW);</li>\n      <li>Irinotesin (HK, PH, SG, TH);</li>\n      <li>Irinox (BD);</li>\n      <li>Iritec (SG);</li>\n      <li>Iritecan (KR);</li>\n      <li>Irnocam (MY);</li>\n      <li>Irotin (BD);</li>\n      <li>Itoxaril (EC);</li>\n      <li>Kampto (UA);</li>\n      <li>Linatecan (PE);</li>\n      <li>Lritecin (KR);</li>\n      <li>Pipetecan (AR);</li>\n      <li>Romisan (ID);</li>\n      <li>Strynotek (UA);</li>\n      <li>Tekamen (MY);</li>\n      <li>Terican (MX);</li>\n      <li>Topotecin (JP);</li>\n      <li>Vizyryn (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bagatell R, London WB, Wagner LM, et al, &quot;Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study,&quot; <i>J Clin Oncol</i>, 2011, 29(2):208-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/21115869/pubmed\" target=\"_blank\" id=\"21115869\">21115869</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2011;29(31):4189-4198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/21947834/pubmed\" target=\"_blank\" id=\"21947834\">21947834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bomgaars L, Kerr J, Berg S, et al, &quot;A Phase I Study of Irinotecan Administered on a Weekly Schedule in Pediatric Patients,&quot;  <i>Pediatr Blood Cancer</i>, 2006, 46(1):50-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/15768380/pubmed\" target=\"_blank\" id=\"15768380\">15768380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bomgaars LR, Bernstein M, Krailo M, et al, &quot;Phase II Trial of Irinotecan in Children With Refractory Solid Tumors: A Children's Oncology Group Study,&quot; <i>J Clin Oncol</i>, 2007, 25(29):4622-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/17925558/pubmed\" target=\"_blank\" id=\"17925558\">17925558</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Casey DA, Wexler LH, Merchant MS, et al, &ldquo;Irinotecan and Temozolomide for Ewing Sarcoma: The Memorial Sloan-Kettering Experience,&rdquo;  <i>Pediatr Blood Cancer</i>, 2009, 53(6):1029-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/19637327/pubmed\" target=\"_blank\" id=\"19637327\">19637327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cirillo M, Musola M, Cassandrini PA, Lunardi G, Venturini M. Irinotecan during pregnancy in metastatic colon cancer. <i>Tumori</i>. 2012;98(6):155e-157e.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/23389374/pubmed\" target=\"_blank\" id=\"23389374\">23389374</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cosetti M, Wexler LH, Calleja E, et al, &ldquo;Irinotecan for Pediatric Solid Tumors: The Memorial Sloan-Kettering Experience,&rdquo; <i>J Pediatr Hematol Oncol</i>, 2002, 24(2):101-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/11990694/pubmed\" target=\"_blank\" id=\"11990694\">11990694</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd J, Mirza I, Sachs B, et al, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo; <i>Semin Oncol</i>, 2006, 33(1):50-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/16473644/pubmed\" target=\"_blank\" id=\"16473644\">16473644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furman WL, Navid F, Daw NC, et al, &quot;Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors,&quot; <i>J Clin Oncol</i>, 2009, 27(27):4599-604.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/19687340/pubmed\" target=\"_blank\" id=\"19687340\">19687340</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gajjar A, Chintagumpala MM, Bowers DC, et al, &ldquo;Effect of Intrapatient Dosage Escalation of Irinotecan on Its Pharmacokinetics in Pediatric Patients Who Have High-Grade Gliomas and Receive Enzyme-Inducing Anticonvulsant Therapy,&rdquo; <i>Cancer</i>, 2003, 97(9 Suppl):2374-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/12712459/pubmed\" target=\"_blank\" id=\"12712459\">12712459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Janus N, Thariat J, Boulanger H, et al, &quot;Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,&quot; <i>Ann Oncol</i>, 2010, 21(7):1395-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/20118214/pubmed\" target=\"_blank\" id=\"20118214\">20118214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kushner BH, Kramer K, Modak S, et al, &quot;Five-Day Courses of Irinotecan as Palliative Therapy for Patients With Neuroblastoma,&quot; <i>Cancer</i>, 2005, 103(4):858-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/15637685/pubmed\" target=\"_blank\" id=\"15637685\">15637685</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ma MK, Zamboni WC, Radomski KM, et al, &quot;Pharmacokinetics of Irinotecan and Its Metabolites SN-38 and APC in Children With Recurrent Solid Tumors After Protracted Low-Dose Irinotecan,&quot; <i>Clin Cancer Res</i>, 2000, 6(3):813-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/10741701/pubmed\" target=\"_blank\" id=\"10741701\">10741701</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mascarenhas L, Lyden ER, Breitfeld PP, et al, &quot;Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group,&quot; <i>J Clin Oncol</i>, 2010, 28(30):4658-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/20837952/pubmed\" target=\"_blank\" id=\"20837952\">20837952</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGregor LM, Stewart CF, Crews KR, et al, &quot;Dose Escalation of Intravenous Irinotecan Using Oral Cefpodoxime: A Phase I Study in Pediatric Patients With Refractory Solid Tumors,&quot; <i>Pediatr Blood Cancer</i>, 2012, 58(3):372-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/21509928/pubmed\" target=\"_blank\" id=\"21509928\">21509928</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McNall-Knapp RY, Williams CN, Reeves EN, et al, &quot;Extended Phase I Evaluation of Vincristine, Irinotecan, Temozolomide, and Antibiotic in Children With Refractory Solid Tumors,&quot; <i>Pediatr Blood Cancer</i>, 2010, 54(7):909-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/20405511/pubmed\" target=\"_blank\" id=\"20405511\">20405511</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgenstern DA, Baruchel S, Irwin MS. Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy. <i>J Pediatr Hematol Oncol</i>. 2013;35(5):337-347.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/23703550/pubmed\" target=\"_blank\" id=\"23703550\">23703550</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappo AS, Lyden E, Breitfeld P, et al, &quot;Two Consecutive Phase II Window trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group,&quot; <i>J Clin Oncol</i>, 2007, 25(4):362-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/17264331/pubmed\" target=\"_blank\" id=\"17264331\">17264331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Ann Oncol</i>. 2010;21(suppl 5):v232-v243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/20555089/pubmed\" target=\"_blank\" id=\"20555089\">20555089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taylor J, Amanze A, Di Federico E, Verschraegen C. Irinotecan use during pregnancy. <i>Obstet Gynecol</i>. 2009;114(2 Pt 2):451-452.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/19622957/pubmed\" target=\"_blank\" id=\"19622957\">19622957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vassal G, Couanet D, Stockdale E, et al, &quot;Phase II Trial of Irinotecan in Children With Relapsed or Refractory Rhabdomyosarcoma: A Joint Study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group,&quot; <i>J Clin Oncol</i>, 2007, 25(4):356-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/17264330/pubmed\" target=\"_blank\" id=\"17264330\">17264330</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner LM, Crews KR, Stewart CF, et al, &quot;Reducing Irinotecan-Associated Diarrhea in Children,&quot; <i>Pediatr Blood Cancer</i>, 2008, 50(2):201-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/17570704/pubmed\" target=\"_blank\" id=\"17570704\">17570704</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner LM, McAllister N, Goldsby RE, et al, &quot;Temozolomide and Intravenous Irinotecan for Treatment of Advanced Ewing Sarcoma,&quot; <i>Pediatr Blood Cancer</i>, 2007, 48(2):132-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/16317751/pubmed\" target=\"_blank\" id=\"16317751\">16317751</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner LM, &quot;Oral Irinotecan for Treatment of Pediatric Solid Tumors: Ready for Prime Time?&quot; <i>Pediatr Blood Cancer</i>, 2010, 54(5):661-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/20108333/pubmed\" target=\"_blank\" id=\"20108333\">20108333</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner LM, Perentesis JP, Reid JM, et al, &quot;Phase I Trial of Two Schedules of Vincristine, Oral irinotecan, and Temozolomide (VOIT) for Children With Relapsed or Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Study,&quot; <i>Pediatr Blood Cancer</i>, 2010a, 54(4):538-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/20049936/pubmed\" target=\"_blank\" id=\"20049936\">20049936</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weigel BJ, Lyden E, Anderson JR, et al. Intensive multiagent therapy, including dose-compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide, irinotecan, and radiation, in patients with high-risk rhabdomyosarcoma: a report from the Children's Oncology Group. <i>J Clin Oncol</i>. 2016;34(2):117-122.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/irinotecan-conventional-pediatric-drug-information/abstract-text/26503200/pubmed\" target=\"_blank\" id=\"26503200\">26503200</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13238 Version 196.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708954\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F184455\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F184456\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1048038\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1048030\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F184432\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F184417\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1048042\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132622\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F184448\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1048041\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3401643\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F184499\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F184438\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F184421\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26023250\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F184487\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F184426\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F184428\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F184440\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1048037\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F184420\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F184437\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323228\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F184441\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13238|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=irinotecan-conventional-drug-information\" class=\"drug drug_general\">Irinotecan (conventional): Drug information</a></li><li><a href=\"topic.htm?path=irinotecan-conventional-patient-drug-information\" class=\"drug drug_patient\">Irinotecan (conventional): Patient drug information</a></li></ul></div></div>","javascript":null}